ITM Appoints Dr. Sebastian Marx as Chief Business Officer and Member of Executive Board
22 juil. 2022 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, July 22, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Sebastian Marx to its Executive Board...
ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177
21 juil. 2022 05h21 HE
|
ITM Isotope Technologies Munich SE
ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs’ Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA Complex for GD2-positive...
ITM: New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope
21 juin 2022 11h45 HE
|
ITM Isotope Technologies Munich SE
First-of-a-kind Isotope Production System continues to progress towards commercial, industrial-scale production of medical isotopes for cancer therapeutics ONTARIO, CANADA, and MUNICH, GERMANY – June...
ITM to Host Symposium on Actinium-225 Targeted Radionuclide Therapy and to Present Phase III COMPOSE Trial Design at the Theranostics World Congress
15 juin 2022 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, June 15, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will host an industry-sponsored lunch symposium on...